Gonzalo Montero Martin: A Breakthrough in HLA Nomenclature for Transplant Evaluation
Gonzalo Montero Martin, HLA Director In Training, shared a post onLinkedIn about a recent article by Steven G. E. Marsh et al, published in HLA Immune Response Genetics:
“HLA Nomenclature History in the making.
Huge congratulations and gratitude to everyone who has made this possible, especially Dr Steven Marsh, Dr Marcelo Fernandez-Vina, Dr Kazutoyo Osoegawa and other co-authors and members of the WHO HLA Nomenclature Committee.
This breakthrough ultimately means a higher level of understanding and accuracy in the definition of HLA antigens and serotypes in order to better evaluate their targeted anti-HLA antibodies and their specificities, which critically determine HLA sensitization categories for solid organ candidate recipients in the waitlist as well as for bone marrow recipients to better prevent graft loss and relapse risk and also to improve transfusion support for refractory platelets patients. This achievement means a tremendous impact for the next generation in the transplant field. Collaboration and sharing can definitely make a difference.
Back at Stanford Blood Center HLA Laboratory when I was working as a Research associate in late 2017, I can still remember vividly being in that R&D lab meeting room with Tamara Vayntrub, Susan Twietmeyer, Deborah Hiraki, Lisa Creary, Sridevi Gangavarapu and Kalyan Mallempati as well as others where we all witnessed and listened to Dr Marcelo asking Dr Kazutoyo: after all these years of experience and thorough literature review, I have in my mind all these additional key aminoacid residues positions that could much better define and explain serological HLA antigen equivalents which we can identify as serotypes.
Can you Kazu develop a bioinformatics tool in order to systematically and thoroughly evaluate all these key residues across all main HLA classical genes with the thousands of different allele variants described?
The rest was history.”
Title: Nomenclature for Factors of the HLA System, 2026
Authors: Steven G. E. Marsh, Kazutoyo Osoegawa, Walter F. Bodmer, Ronald E. Bontrop, Mary N. Carrington, Henry A. Erlich, Sebastiaan Heidt, Rhonda Holdsworth, Wolfgang R. Mayr, Martin Maiers, Peter Parham, Effie W. Petersdorf, James Robinson, John Trowsdale, Marcelo Fernández-Viña
Read Full Article on HLA Immune Response Genetics

Stay updated with Hemostasis Today.
-
Feb 28, 2026, 11:47Abdul Mannan: Paradox of Bleeding and Clotting in Uremic Coagulopathy
-
Feb 28, 2026, 11:40Jim Hoffman: Could Extracorporeal Removal of NETs Become a ‘Holy Grail’ Therapy Across Multiple Diseases?
-
Feb 27, 2026, 18:30Sanjeev Saksena: From Isolated Case Reports to Clinical Evidence for Post-Ablation Myocardial Ischemia
-
Feb 27, 2026, 18:21Priya Prasad: Can Money Buy Blood?
-
Feb 27, 2026, 18:19Trulee Cardona: Hemophilia Care in Uzbekistan and Why It Matters
-
Feb 27, 2026, 18:19Bartosz Hudzik: Do Elevated Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Otherwise Healthy Women?
-
Feb 27, 2026, 18:14Mohamed Sikkander Abdul Razak: Factor XIa Inhibitors Show Promise With Lower Bleeding Risk
-
Feb 27, 2026, 18:09Hariom Rajput: Early Recognition and Prevention of Deep Vein Thrombosis
-
Feb 27, 2026, 18:08Karen Fahey: What If the Blood Products You Rely On Weren’t Safe?